UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

MA13.06 Amivantamab, Lazertinib Plus Platinum-based Chemotherapy in EGFR-mutated Advanced NSCLC: Updated Results from CHRYSALIS-2

Journal of thoracic oncology, 2023-11, Vol.18 (11), p.S146-S147

2023

Volltextzugriff (PDF)

MA07.04 Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy in Relapsed/Refractory EGFR-mutant NSCLC

Journal of thoracic oncology, 2022-09, Vol.17 (9), p.S68

2022

Volltextzugriff (PDF)

Predictors of bone biomarkers in children and adolescents with Crohn disease

Bone (New York, N.Y.), 2007-06, Vol.40 (6), p.S81-S82

2007

Volltextzugriff (PDF)

20P Risk and management of intracranial progression on amivantamab in epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins)-mutated non-small cell lung cancer (NSCLC)

Annals of oncology, 2022-04, Vol.33, p.S38-S39

2022

Volltextzugriff (PDF)

EP08.02-016 Frontline and Post-Osimertinib Therapy for EGFR-mutant Advanced NSCLC: Treatment Patterns, Outcomes, Healthcare Use and Costs

Journal of thoracic oncology, 2022-09, Vol.17 (9), p.S404-S405

2022

Volltextzugriff (PDF)

1193MO Amivantamab plus lazertinib in post-osimertinib, post-platinum chemotherapy EGFR-mutant non-small cell lung cancer (NSCLC): Preliminary results from CHRYSALIS-2

Annals of oncology, 2021-09, Vol.32, p.S952-S953

2021

Volltextzugriff (PDF)

1247P Management of infusion-related reactions (IRRs) in patients receiving amivantamab

Annals of oncology, 2021-09, Vol.32, p.S981-S982

2021

Volltextzugriff (PDF)

P1.16-01 Amivantamab and Lazertinib in Treatment-Naive EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)

Journal of thoracic oncology, 2022-09, Vol.17 (9), p.S126

2022

Volltextzugriff (PDF)

30 Long-term efficacy, safety, and predictors of response to amivantamab among patients with post-platinum EGFR Ex20ins-mutated advanced NSCLC

Journal of thoracic oncology, 2023-04, Vol.18 (4), p.S36-S37

2023

Volltextzugriff (PDF)

Improvement in a biomarker of bone formation during infliximab therapy in pediatric Crohn disease: Results of the REACH study

Bone (New York, N.Y.), 2007-06, Vol.40 (6), p.S81-S81

2007

Volltextzugriff (PDF)

OA21.04 Amivantamab in Patients with Advanced NSCLC and MET Exon 14 Skipping Mutation: Results from the CHRYSALIS Study

Journal of thoracic oncology, 2023-11, Vol.18 (11), p.S93-S94

2023

Volltextzugriff (PDF)

OA15.03 Amivantamab in Non-small Cell Lung Cancer (NSCLC) with MET Exon 14 Skipping (METex14) Mutation: Initial Results from CHRYSALIS

Journal of thoracic oncology, 2021-10, Vol.16 (10), p.S874-S875

2021

Volltextzugriff (PDF)

P3.04-008 A Phase 1b/2 Study of Atezolizumab With or Without Daratumumab in Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

Journal of thoracic oncology, 2017-11, Vol.12 (11), p.S2288-S2288

2017

Volltextzugriff (PDF)

1192MO Amivantamab monotherapy and in combination with lazertinib in post-osimertinib EGFR-mutant NSCLC: Analysis from the CHRYSALIS study

Annals of oncology, 2021-09, Vol.32, p.S951-S952

2021

Volltextzugriff (PDF)

P1.01-94 JNJ-61186372, an EGFR-cMet Bispecific Antibody, in EGFR Exon 20 Insertion-Driven Advanced NSCLC

Journal of thoracic oncology, 2019-10, Vol.14 (10), p.S397-S398

2019

Volltextzugriff (PDF)

1258O Amivantamab (JNJ-61186372), an EGFR-MET bispecific antibody, in combination with lazertinib, a 3rd-generation tyrosine kinase inhibitor (TKI), in advanced EGFR NSCLC

Annals of oncology, 2020-09, Vol.31, p.S813-S813

2020

Volltextzugriff (PDF)

Skeletal Health of Children and Adolescents With Inflammatory Bowel Disease

Journal of pediatric gastroenterology and nutrition, 2012-04, Vol.54 (4), p.571-571

2012

Volltextzugriff (PDF)

OA04.04 Amivantamab in Post-platinum EGFR Exon 20 Insertion Mutant Non-small Cell Lung Cancer

Journal of thoracic oncology, 2021-03, Vol.16 (3), p.S108-S109

2021

Volltextzugriff (PDF)

Hepatosplenic T-Cell Lymphoma in an Adolescent Patient after Immunomodulator and Biologic Therapy for Crohn Disease

Journal of pediatric gastroenterology and nutrition, 2005-02, Vol.40 (2), p.220-222

2005

Volltextzugriff (PDF)

P-112: The association between drug levels, anti-drug antibodies, and therapeutic response during infliximab therapy in pediatric Crohn’s disease

Journal of Crohn's and colitis, 2014-09, Vol.8, p.S434-S434

2014

Volltextzugriff (PDF)

Body Composition Abnormalities in Long-Term Survivors of Pediatric Hematopoietic Stem Cell Transplantation

The Journal of pediatrics, 2012-01, Vol.160 (1), p.122-128

2012

Volltextzugriff (PDF)

Daratumumab Plus Atezolizumab in Previously Treated Advanced or Metastatic NSCLC: Brief Report on a Randomized, Open-Label, Phase 1b/2 Study (LUC2001 JNJ-54767414)

JTO clinical and research reports, 2021-02, Vol.2 (2), p.100104, Article 100104

2021

Volltextzugriff (PDF)

Interpretation of Biomarkers of Bone Metabolism in Children: Impact of Growth Velocity and Body Size in Healthy Children and Chronic Disease

The Journal of pediatrics, 2008-10, Vol.153 (4), p.484-490.e2

2008

Volltextzugriff (PDF)

Increases in Sex Hormones during Anti-Tumor Necrosis Factor α Therapy in Adolescents with Crohn's Disease

The Journal of pediatrics, 2016-04, Vol.171, p.146-152.e2

2016

Volltextzugriff (PDF)

Cardiac ischemia during hemolytic uremic syndrome

Pediatric nephrology (Berlin, West), 2003-03, Vol.18 (3), p.286-289

2003

Volltextzugriff (PDF)

1 – 25 von 48

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(48)
Mit Volltextzugriff
(45)

Publikationsform

Artikel
(48)

Sprache

Englisch
(48)

Erscheinungsjahr

n.n

Thema

Humans
(22)
Life Sciences & Biomedicine
(22)
Science & Technology
(22)
Female
(18)
Male
(17)
Child
(16)
Adolescent
(14)
Pediatrics
(10)
Child, Preschool
(9)
Crohn Disease - Drug Therapy
(9)
Gastroenterology & Hepatology
(9)
Adult
(8)
Biological And Medical Sciences
(7)
Medical Sciences
(7)
Body Composition
(5)
Crohn Disease - Physiopathology
(5)
Gastroenterology And Hepatology
(5)
Treatment Outcome
(5)
Young Adult
(5)
Antibodies, Monoclonal - Therapeutic Use
(4)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

MA13.06 Amivantamab, Lazertinib Plus Platinum-based Chemotherapy in EGFR-mutated Advanced NSCLC: Updated Results from CHRYSALIS-2

MA07.04 Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy in Relapsed/Refractory EGFR-mutant NSCLC

Predictors of bone biomarkers in children and adolescents with Crohn disease

20P Risk and management of intracranial progression on amivantamab in epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins)-mutated non-small cell lung cancer (NSCLC)

EP08.02-016 Frontline and Post-Osimertinib Therapy for EGFR-mutant Advanced NSCLC: Treatment Patterns, Outcomes, Healthcare Use and Costs

1193MO Amivantamab plus lazertinib in post-osimertinib, post-platinum chemotherapy EGFR-mutant non-small cell lung cancer (NSCLC): Preliminary results from CHRYSALIS-2

1247P Management of infusion-related reactions (IRRs) in patients receiving amivantamab

P1.16-01 Amivantamab and Lazertinib in Treatment-Naive EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)

30 Long-term efficacy, safety, and predictors of response to amivantamab among patients with post-platinum EGFR Ex20ins-mutated advanced NSCLC

Improvement in a biomarker of bone formation during infliximab therapy in pediatric Crohn disease: Results of the REACH study

OA21.04 Amivantamab in Patients with Advanced NSCLC and MET Exon 14 Skipping Mutation: Results from the CHRYSALIS Study

OA15.03 Amivantamab in Non-small Cell Lung Cancer (NSCLC) with MET Exon 14 Skipping (METex14) Mutation: Initial Results from CHRYSALIS

P3.04-008 A Phase 1b/2 Study of Atezolizumab With or Without Daratumumab in Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

1192MO Amivantamab monotherapy and in combination with lazertinib in post-osimertinib EGFR-mutant NSCLC: Analysis from the CHRYSALIS study

P1.01-94 JNJ-61186372, an EGFR-cMet Bispecific Antibody, in EGFR Exon 20 Insertion-Driven Advanced NSCLC

1258O Amivantamab (JNJ-61186372), an EGFR-MET bispecific antibody, in combination with lazertinib, a 3rd-generation tyrosine kinase inhibitor (TKI), in advanced EGFR NSCLC

Skeletal Health of Children and Adolescents With Inflammatory Bowel Disease

OA04.04 Amivantamab in Post-platinum EGFR Exon 20 Insertion Mutant Non-small Cell Lung Cancer

Hepatosplenic T-Cell Lymphoma in an Adolescent Patient after Immunomodulator and Biologic Therapy for Crohn Disease

P-112: The association between drug levels, anti-drug antibodies, and therapeutic response during infliximab therapy in pediatric Crohn’s disease

Body Composition Abnormalities in Long-Term Survivors of Pediatric Hematopoietic Stem Cell Transplantation

Daratumumab Plus Atezolizumab in Previously Treated Advanced or Metastatic NSCLC: Brief Report on a Randomized, Open-Label, Phase 1b/2 Study (LUC2001 JNJ-54767414)

Interpretation of Biomarkers of Bone Metabolism in Children: Impact of Growth Velocity and Body Size in Healthy Children and Chronic Disease

Increases in Sex Hormones during Anti-Tumor Necrosis Factor α Therapy in Adolescents with Crohn's Disease

Cardiac ischemia during hemolytic uremic syndrome

Suchergebnisse filtern